
Drug Approvals
Sotyktu™ (Deucravacitinib) Recommended by the National Institute for Health and Care Excellence (NICE) for use in England as a First-in-class Treatment Option for Moderate to Severe Plaque Psoriasis in Adults
Bristol Myers Squibb (BMS) announced last week that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib,